PET imaging of differentiated thyroid cancer with thyrotropin-alfa.

ABSTRACT: Thyrotropin-alfa is an FDA approved recombinant human TSH agonist. This study represents a preclinical evaluation of thyrotropin-alfa as a thyroid-stimulating hormone receptor (TSHR)-targeted PET radiopharmaceutical, [⁸⁹Zr]Zr-thyrotropin-alfa. [⁸⁹Zr]Zr-thyrotropin-alfa was synthesized by conjugating p-SCN-Bn-deferoxamine (DFO) to thyrotropin-alfa in a molar ratio of 3:1 (DFO:thyrotropin-alfa) and radiolabeling with ⁸⁹Zr (t_1/2 = 78.4 h, β⁺ = 22.7%) at a molar activity of 25.9 MBq/nmol. [⁸⁹Zr]Zr-thyrotropin-alfa uptake was assessed in THJ529T and FTC133 cells stably transduced with the TSHR and compared to their low-expressing wild-type. Studies included a combination of in vitro cell uptake, in vivo PET imaging, and ex vivo b

SUBMITTER: Gimblet GR 

PROVIDER: S-EPMC11965406 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature